Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

In guidelines, a combination therapy of two or more antihypertensives is recommended for treatment of hypertension where monotherapy is ineffective. Although diuretics or calcium channel blockers are commonly used as add-ons to angiotensin receptor blocker (ARB), the most effective and safe combination has not been established. In this randomized 4-month study, the efficacy and safety were compared between an ARB/diuretics (losartan/hydrochlorothiazide [HCTZ]) combination and the most prescribed combination, ARB/calcium channel blocker (candesartan/amlodipine) in hypertensive patients for whom 8 mg/day of candesartan proved ineffective. After 36 patients were recruited and allocated into two groups, changes in blood pressure (BP) and laboratory values were analyzed in 31 patients: 16 patients received losartan (50 mg/day)/HCTZ (12.5 mg/day) (L/H group), and 15 patients received candesartan (8 mg/day)/amlodipine (5 mg/day) (C/A group) after 5 patients were withdrawn. After 4 months, L/H significantly (p<0.001) reduced mean systolic BP (SBP)/diastolic BP (DBP) from baseline 160/89±13/11 mmHg to 140/80±9/8 mmHg, and C/A reduced BP from 161/90±10/11 mmHg to 141/79±10/7 mmHg. The efficacy in reducing BP was similar between the two combination therapies. L/H significantly reduced serum potassium, but within the normal range, and did not increase serum uric acid or serum triglyceride. With L/H, the percentage of patients who attained the BP goal in SBP was higher in elderly patients than in younger patients. As L/H is more cost-effective than candesartan/amlodipine and has fewer adverse effects on uric acid and other metabolic parameters than diuretic monotherapy, it is concluded to be useful for the management of hypertension.

[1]  S. Umemura,et al.  Current Status of Antihypertensive Prescription and Associated Blood Pressure Control in Japan , 2006, Hypertension Research.

[2]  Subcommittee Guidelines.  Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). , 2006, Hypertension research : official journal of the Japanese Society of Hypertension.

[3]  Jian-Mei Li,et al.  Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice , 2005, Journal of hypertension.

[4]  H. Iwao,et al.  Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[5]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[6]  M. Nakashima,et al.  Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[7]  G. Mancia,et al.  Tolerability and treatment compliance with angiotensin II receptor antagonists. , 2003, American journal of hypertension.

[8]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[9]  J. Laragh.  Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. , 2001, American journal of hypertension.

[10]  P. Pentikäinen,et al.  Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well‐being , 1997, Journal of hypertension.

[11]  S. Snapinn,et al.  Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. , 1996, Archives of internal medicine.

[12]  C. Mörlin,et al.  Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. , 1994, Blood pressure.

[13]  J. Ménard.  Critical assessment of combination therapy development. , 1993, Blood pressure. Supplement.

[14]  A. Ribeiro,et al.  Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. , 1992, Hypertension.

[15]  M. Brodie,et al.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. , 1990, BMJ.

[16]  D. G. Aycock,et al.  The Effect of Low‐Dose Hydrochlorothiazide on Blood Pressure, Serum Potassium, and Lipoproteins , 1986, Pharmacotherapy.